drug
suvorexant
Marketedupdated 5mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying suvorexant
- phase2Sleep Trial to Prevent Alzheimer's Disease
- phase3A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
- phase4Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
- phase2REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant
- phase2Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
- phase4Suvorexant and Sleep/Delirium in ICU Patients
- phase1A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
- phase4A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 20, 2029
~3.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- May 29, 2033formulationUS 10098892
- May 29, 2033formulationUS 10098892
- May 29, 2033formulationUS 10098892
- May 29, 2033formulationUS 10098892
- May 29, 2033formulationUS 11980623
- May 29, 2033formulationUS 11980623
- May 29, 2033formulationUS 11980623
- May 29, 2033formulationUS 11980623
- Nov 20, 2029compositionUS 79517973.1y
- Nov 20, 2029compositionUS 79517973.1y
- Nov 20, 2029compositionUS 79517973.1y
- Nov 20, 2029compositionUS 79517973.1y
News(1)
- ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing itAs the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.fiercebiotech · 1mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that